Amyloid aggregates of the amyloid-␤ (A␤) peptide are implicated in the pathology of Alzheimer's disease. Anti-A␤ monoclonal antibodies (mAbs) have been shown to reduce amyloid plaques in vitro and in animal studies. Consequently, passive immunization is being considered for treating Alzheimer's, and anti-A␤ mAbs are now in phase II trials. We report the isolation of two mAbs (PFA1 and PFA2) that recognize A␤ monomers, protofibrils, and fibrils and the structures of their antigen binding fragments (Fabs) in complex with the A␤(1-8) peptide DAEFRHDS. The immunodominant EFRHD sequence forms salt bridges, hydrogen bonds, and hydrophobic contacts, including interactions with a striking WWDDD motif of the antigen binding fragments. We also show that a similar sequence (AKFRHD) derived from the human protein GRIP1 is able to cross-react with both PFA1 and PFA2 and, when cocrystallized with PFA1, binds in an identical conformation to A␤(1-8). Because such cross-reactivity has implications for potential side effects of immunotherapy, our structures provide a template for designing derivative mAbs that target A␤ with improved specificity and higher affinity.
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amyloid ͉ crystal structure ͉ EFRH ͉ monoclonal antibody ͉ EFRHD N ormally soluble proteins and peptides can sometimes aggregate into insoluble, self-assembled filamentous aggregates, including amyloid and amyloid-like structures. Current interest in amyloid fibrils and related aggregates arises from their involvement in diseases such as Alzheimer's disease (AD), type 2 diabetes, prion diseases, and other protein misfolding disorders (1) . Because aggregates of the amyloid-␤ (A␤) peptide have been implicated in the molecular mechanism of AD, reversing or preventing A␤ aggregation is an important prospective approach to AD therapy. Antibodies capable of binding monomeric/low molecular weight forms of A␤ (in the periphery) or aggregated states of A␤ (in the brain) reduce the amyloid burden in animal studies (2) . Passive immunization with humanized anti-A␤ monoclonal antibodies (mAbs) (3) is in phase II trials as an Alzheimer's therapy (www.elan.com/researchdevelopment/ Alzheimers/). Because the EFRHD motif (A␤ residues 3-7) appears to be an immunodominant segment of A␤ (4, 5) and immunization to the EFRH sequence rescues cognitive function in mouse models of AD (6, 7) , it is important to understand the structural basis of antibody recognition of this sequence.
At least three mechanisms for immunotherapy of AD have been proposed. Two mechanisms, microglial activation (8, 9) and catalytic dissolution (10) , require that the antibody enter the central nervous system; the other mechanism, sometimes called the peripheral sink hypothesis, does not. In the microglial activation mechanism (8) , antibodies bind to amyloid plaques, triggering microglia via their Fc receptors. As evidence for this mechanism, A␤(1-42) immunization elicits synthesis of anti-A␤ antibodies and causes A␤-reactive microglial cells to appear around plaques (8) . In catalytic dissolution, antibodies are hypothesized to act as chaperones, catalyzing the structural change of the A␤ peptide from the ␤-strand to an alternative conformation less prone to aggregation (10) . Consistent with this mechanism, the efficacy of a given mAb depends on the A␤ sequence element it binds; thus, the mAb 6C6, which recognizes the A␤ N terminus, is three times more effective in disaggregating A␤ fibrils than the mAb 1C2, which binds to the central residues of A␤ (10) . In the peripheral sink hypothesis (3), antibodies bind to A␤ in the bloodstream, shifting the distribution of A␤ between the brain and the peripheral circulatory system and thereby leading to a net efflux of A␤ from the central nervous system to plasma, where it is degraded. Thus, DeMattos et al. (3) observed a 1,000-fold increase in the plasma A␤ levels in A␤-overproducing transgenic mice after peripheral administration of m266, an mAb directed against the central domain of A␤.
All three mechanisms require antibody binding to A␤ in either monomer or aggregated forms. Because it remains unclear which of these mechanisms might ultimately make contributions to AD therapy, the most appropriate antibodies are those equally capable of recognizing all assembly forms of A␤ peptides. Although anti-A␤ mAbs have been described [10D5 (11); 3D6 and 16C11 (9); m266 (12); NAB61 (13); and Ab42.2, Ab40.1, and Ab9 (14) ], neither their structural details nor their specificities for different forms of A␤ have been reported. Thus, the structural basis of A␤ binding, which lies at the heart of all three mechanisms, remains unknown.
When immunizing mice to generate antibodies against A␤, one may choose from several different states of A␤: monomers (11, 12, 14, 15) , oligomers (13), protofibrils, or fibrils (14, 16) . Transient, metastable, spherical oligomers, and protofibrils are observed during the lag phase (an incubation period of up to several days preceding amyloid fibril growth phase) of spontaneous A␤ fibril growth in vitro from high concentrations of A␤ and, indeed, during amyloid growth by many peptides and proteins (17) . Because the current wisdom is that spherical oligomers and/or protofibrils are the most important toxic species in AD and other amyloid-associated neurodegenerative diseases (18) , the prevailing controversy about whether these intermediates are on-or off-pathway in amyloid formation (17) does not impact the validity of targeting these species therapeutically. Because isolated A␤(1-40) protofibrils can, depending on conditions, either dissociate (19) or progress to mature fibrils, their use as immunogens is problematic. Protofibrils can be stabilized, however, by the small molecule calmidazolium (CLC), which allows the preparation of stable protofibrils for structural studies and for use as an antigen. These CLC-stabilized protofibrils (i) exhibit EM images and hydrogen-deuterium exchange kinetics essentially identical to normal A␤ protofibrils, (ii) share with protofibrillar assembly intermediates a poor ability to seed elongation of the monomer, and (iii) develop into amyloid fibrils, in analogy to normal protofibrils, but at a much slower rate than the latter (20) .
We report here the isolation of two murine IgG2a mAbs, anti-protofibril antibodies (PFAs) PFA1 and PFA2, from mice challenged with a CLC-stabilized protofibril form of A␤ and the structures of their antigen binding fragments (Fabs) in complex with the A␤(1-8) peptide DAEFRHDS and with the AKFRHD peptide from the human glutamate receptor interacting protein, GRIP1 (21) . The Fab fragments exhibit binding to A␤ monomers in the 20-40 nM range, and this binding is significantly impaired or eliminated in A␤(1-40) mutants in which a single residue in the 3-7 segment is replaced with alanine. The full IgG molecules bind significantly better than Fab fragments to A␤ fibrils and protofibrils (0.1-0.2 nM), apparently because of an avidity effect. Our structures reveal that binding of both mAbs to the EFRHD sequence is mediated by a combination of salt bridges, hydrogen bonds, and hydrophobic contacts, including, in both cases, interactions with a striking WWDDD motif in the second heavy-chain (H) complementarity determining region (CDR) (CDR-H2). These structures provide a molecular basis for A␤ recognition that can be exploited in the design of derivative mAbs of enhanced affinity and specificity (22, 23) .
Results
Antibody Isolation and Screening. To isolate aggregate-specific mAbs (16), we injected mice with CLC-stabilized A␤ protofibrils (20) and screened candidate hybridoma clones for persistent binding to protofibrils in the presence of large excesses of monomeric A␤. A number of unique IgG and IgM mAbs, all capable of binding to A␤ protofibrils, were isolated. Two of the IgGs, PFA1 and PFA2, are described here. The mAbs were screened for protofibril affinity in competition assays with A␤ (1-40) 39.0 nM (PFA1) and 25 nM (PFA2). The significantly enhanced binding of the IgG forms of PFA1 and PFA2 to A␤ aggregates, compared with the monovalent interaction with A␤, may explain why competition with A␤ monomers was ineffective at eliminating these linear epitope mAbs during the hybridoma screening process.
The binding epitope was determined by SPR analysis of previously described (25, 26) single Ala mutants of A␤(1-40) (Fig. 1b) . Ala mutation at peptide residue (PR) 8 (Fig. 1b) or higher (data not shown) consistently yields WT levels of binding in SPR experiments. The Asp-13 Ala mutant peptide shows little reduction in binding, consistent with the crystal structures discussed below, in which Asp-1 is disordered. Binding is nearly To explore the structural basis of binding, we solved the x-ray structures of the two Fab fragments both alone (apo) and bound to the peptide fragment A␤(1-8) (''PFA1-pep'' and ''PFA2-pep''); the amino acid sequence of A␤ (1-8) is DAEFRHDS. The structures were determined by molecular replacement; the highest resolution structure is at 1.65 Å. Additionally, we crystallized PFA1 with a ''mutant'' A␤(2-7) peptide AKFRHD, whose sequence is found in GRIP1 (residues 110-115), to illustrate the potential for cross reaction (PFA1-E3K). Abbreviated crystallographic data are presented in Table 2 . Full crystallographic data collection and refinement parameters are presented in supporting information (SI) Table 5 . In our three complex structures, at least six residues of the peptide can be traced unambiguously from the electron density maps (Fig. 2a) . In all structures, the electron density for the CDRs is readily traced. The antigen binding site, which lies in a cleft between the light-chain (L) and H variable domains, is formed by four of the six CDRs: CDR-L1, CDR-L3, CDR-H2, and CDR-H3 (sequences are shown in Table 2 ). The A␤(1-8) peptide adopts nearly identical conformations when bound to the two Fabs (C␣ RMS deviation for residues 2-8 is 0.48 Å) (Fig.  2b) , which is not surprising given that PFA1-Fab and PFA2-Fab have identical L and similar H sequences. Table 6 ). In both structures, the main chain of the CDR-H3 and CDR-L1 loops moves (maximum C␣ displacement is 1.7 Å) to accommodate the peptide, alleviating steric clashes. Peptide binding also induces changes in side-chain conformations, with H His-97, Trp-53, and Asp-100C (Kabat numbering is used throughout) changing rotamers with peptide binding (SI Fig. 4) .
The A␤(1-8) peptide binds in a partially extended coil with no evident ␣ or ␤ structure. Complex formation between the A␤(1-8) peptide and mAb buries 494 Å 2 and 528 Å 2 of PFA1 and PFA2, respectively. A striking feature of the CDR regions of both mAbs is the WWDDD motif in CDR-H2. The WWDDD motif is found in other mAbs such as AAO18227 (anti-human Fc), AAB02362 (anti-flu), AAQ24154 (anti-human CD16), AAS00782 (anti-DNA), and Fab28 (anti-HIV1-RT); it appears to be restricted to the IGHV8 subtype (Ig allele nomenclature from the IMGT database of Ig genes) (27) gene sequences, making it an important antigen recognition motif. Our structures provide the first example of the WWDDD motif binding to a positively charged residue and to an adjoining aromatic residue. In our structures, both Trp (W) residues and two of the three Asp (D) residues interact with the bound peptide, particularly residues Phe-4 and Arg-5, making this motif important in epitope recognition (Fig. 2b, SI Fig. 5 , and SI Table 7 ).
The key residues of A␤s for binding PFA1 and PFA2 consist of PRs 3 EFRHD 7 at the A␤ N terminus (shown in Fig. 2b ). They make bulk of the hydrogen bonds, ion-pair, and van der Waals interactions with the Fabs (SI Table 7 ). This EFRHD binding region is entirely consistent with the epitope derived by SPR, as discussed above. The carboxyl group of PR Glu-3 is within hydrogen bonding distance of the side-chain of L His-27D in both PFA1-pep and PFA2-pep. In both complexes, the side- chain of PR Glu-3 hydrogen bonds to L Ser27E (N and OG atoms) and makes some long-range (Ͻ5 Å) ion-pair interactions with the L His-93 side chain. The electrostatic environment of the peptide-binding site is shown in Fig. 3 . PR Phe-4 is buried deep within a binding pocket consisting of H Trp-47, and Trp-52 belonging to the aforementioned WWDDD motif (SI Fig. 5 ) and the L Leu-96 and H His-50 residues and makes edge-on hydrophobic interactions with these residues. PR Phe-4 also makes hydrogen bonds via its main-chain amide N and carbonyl O to the main-chain of L Ser-92 and the side chain of L His-27D, respectively. PR Arg-5 makes salt bridges with H Asp-54 and -56 belonging to the WWDDD motif, whereas the side chain of PR His-6 hydrogen bonds to the side chain of H Asp-100C. Furthermore, PR His-6 makes a parallel -overlap with L Tyr-32. PR Asp-7 N hydrogen bonds to H His-97 O. PR Asp-7 makes hydrogen bonds to the side chain of H His-97 and to L Asn-28 ND2. No hydrogen bonds are made from the Fabs to the terminal residues PR Asp-1 and PR Ser-8. In fact, PR Asp-1 is not visible in the electron density maps in either complex. In both complexes, the amide of PR His-6 makes an intramolecular hydrogen bond to the carbonyl oxygen of Phe-4, stabilizing the peptide conformation.
PFA1 and PFA2 Are Highly Homologous. The similarity of mAbs in binding to A␤ reflects their sequence similarity: Their light chains are identical, expressing the kappa IGKV1-117 allele (27) . The PFA1 and PFA2 heavy chains strongly resemble the product of the IGHV8S7 allele (27) ; they exhibit 92% sequence identity with one another, with four residue differences at the CDRs and one adjacent to CDR-H2 (Table 3) . None of the divergent residues are directly involved in short-range (Ͻ3.5 Å) interactions to the peptide. However, the CDR-H3 regions of PFA1 and PFA2 differ from one another at two adjacent residues (TT vs. NV) that make 3.8-4.8 Å polar interactions with the bound peptide; such longer-range effects may contribute to the nearly 2-fold difference in binding affinity between these two mAbs and the A␤ monomer.
Binding of PFA1 and PFA2 to Related Sequences. Although the binding constants of these mAbs for A␤ are significant and within a therapeutically useful range, the shortness of the A␤ sequence epitope raises possible specificity issues. A BLAST search revealed that the only protein in the human genome containing the AEFRHD sequence is its membrane-associated amyloid precursor protein. Nonetheless, it is possible that human sequences related to AEFRHD might cross-react with antibodies, such as PFA1 and PFA2, causing side effects during passive immunotherapy. Indeed, the SPR studies showed that Ala replacements at residues 3 and 7 of this epitope do not fully eliminate binding. BLAST and FASTAS3 searches yielded six extracellular, secreted, or membrane-associated human proteins featuring sequences matching 5 of the 6 residues of AEFRHD (SI Table 8 ). If we limit our search to the EFRH motif, the dominant binding motif as revealed by our structures and SPR studies, we obtain additional hits (SI Table 8 ).
As a preliminary investigation of the specificity of PFA1 and PFA2 with respect to the human genome, the WT A␤(2-7) peptide AEFRHD and mutants derived from proteins listed in SI Table 8 , AKFRHD, AEIRHD, AEFRSD, and REEFRHEA, were synthesized, and their affinity for the two Fab fragments was determined by SPR. AEIRHD and AEFRSD showed no measurable binding to PFA1 and PFA2. However, we found that PFA1-Fab binds to AKFRHD (a sequence found GRIP1) with an affinity 28 times lower than that at which it binds to AEFRHD (Table 4) . Similarly, SPR studies show that PFA2-Fab also binds to the GRIP1-derived peptide AKFRHD with 35-fold lower affinity than that at which it binds to AEFRHD (Table 4) . Perhaps more significantly, the peptide sequence REEFRHEA, derived from the human receptor-related neurotrophic tyrosine kinase (ROR2), actually binds to PFA1 and PFA2 with approximately twice the affinity of the WT A␤(2-7) peptide AEFRHD (Table 4) . Thus, although the AEFRHD sequence is unique in the known mouse and human proteomes, it has near-matches with several other proteins in both species. These in vitro results do not necessarily imply that the full-length protein will interact with the mAb in vivo; however, they do illustrate the potential for complications from cross-reactivity.
A significant portion of the A␤ found in the brain is Nterminally truncated, and the most prevalent of these modified forms is one lacking residues 1 and 2 and beginning with a pyroglutamate residue (pyroglutamate-Glu A␤). This form is expected to be resistant to exopeptidase digestion and is also more amyloidogenic than full length peptides, suggesting that this A␤ breakdown product might play a significant role in pathology (28) . Because E3 is part of the PFA1/PFA2 epitope, we expected these mAbs to exhibit diminished affinity for pyroglutamate-Glu forms of A␤. In fact, we found that the peptide pGlu-FRHD is bound by the antibodies Ϸ50-to 70-fold less well than the corresponding WT sequence (Table 4) . Thus, although the pathological roles of the pyroglutamate-Glu A␤ peptide and other truncated forms of A␤ is yet to be worked out, in the future it may also be necessary to develop antibodies that effectively bind to these forms.
PFA1
Complexed with the GRIP1 Peptide. The AKFRHD peptide from GRIP1 (whose binding to PFA1 and PFA2 was discussed above) was cocrystallized with PFA1. We observed clear peptide electron density in a PFA1-AKFRHD cocrystal structure. Binding of the AKFRHD (''E3K'') peptide to PFA1 is nearly identical (C␣ RMSD is 0.23 Å) to that of A␤ (1) (2) (3) (4) (5) (6) (7) (8) , except that it is the tail of the substituted lysine residue rather than the glutamate making a hydrogen bond with L Ser-32 (SI Fig. 6 ). The Glu-toLys substitution also results in replacing the favorable ion-pair interaction made by the A␤ peptide to His by a less favorable van der Waals contact formed between two basic residues. Quantitatively, AEFRHD of the A␤ peptide makes Ϸ30% more ionpair interactions (12 vs. 9) at short range (Ͻ4 Å) and Ϸ60% more (18 vs. 11) at medium range (between 4 and 6 Å) than AKFRHD. Because they both make 18 hydrogen bonds, these ion-pairing differences may possibly account for the Ϸ30-fold reduction in binding of the GRIP1 peptide relative to the A␤ peptide.
Discussion
The structures of mAb Fab fragments in complex with an N-terminal A␤ peptide illustrate the molecular basis for A␤ recognition by these mAbs. The interface features a striking WWDDD motif. Residues in the CDR-L1, CDR-L3, CDR-H2, and CDR-H3 loops take part in binding.
The accumulated experience of many efforts to obtain antibodies to A␤ suggests that the N terminus may be the immunodominant epitope of this peptide. Furthermore, if aggregated forms of A␤ are to be targeted in therapy, antibodies to the N terminus will probably be required, given the poor accessibility of other portions of the sequence in aggregates (29, 30) .
In summary, the structures and binding data presented here provide insights into at least one way in which the immune system generates antibodies to bind this epitope, and they also provide the necessary foundation for structure-based design of antibodies with enhanced properties. Structural modifications in the CDR residues, for example, may lead to derivative antibodies with improved binding to the WT sequence and its natural breakdown products (such as the pyroglutamate-Glu A␤ form) and reduced binding to related sequences, such as Ror2, found in the human genome that, if left unaddressed, might lead to significant side reactions in immunotherapy.
Methods
Preparation of disaggregated monomer (31), mature amyloid fibrils (31) , and CLC-stabilized protofibrils (25) was as described. Preparation of hybridoma cell lines and antibody sequencing is described in SI Text. The mAb purification and papain fragmentation protocol was adapted from Goding (ref.
32, chap. 9).
IgG affinities for A␤(1-40) fibrils and protofibrils were measured by using a microtiter plate assay as described in ref. 16 . A full description of the SPR binding experiments is in SI Text. Briefly, binding studies were performed at 20°C by using BIAcore (Uppsala, Sweden) 2000 optical biosensors equipped with CM5 sensor chips.
Reagents 37-47 from the Hampton Index (33) were used for initial screening, and some initial apo hits were obtained by using the PHOENIX crystallization robot (Art Robbins Instruments, Sunnyvale, CA). Data were indexed, integrated, and scaled with the HKL2000 package (34) . The original PFA2 triclinic apo structure was solved by molecular replacement, using the constant (CLϩCH1) and variable portions of FAB4C6 (PDB ID code 1NCW) separately (35) . Protein rebuilding, including water-picking, was performed in Coot (36); refinement was conducted with Refmac5 (37) . A partially refined PFA2 apo model was idealized and used for solution of the other structures. Structures were validated with SFCHECK (38), PROCHECK (39) , and MOLPROBITY (40) .
Abbreviated data collection and refinement statistics appear in Table 2 . Full crystallization conditions, validation information, and statistics appear in SI Table 5 and SI Text. Buried surface area was calculated with Areaimol with a 1.4-Å probe radius. A␤(2-7), Grip1(110 -115), Ror2(518 -525), and pyroglutamic A␤(3-8 
